Develops drugs for acute radiation syndrome and oncology-related conditions.
Sep 2025Revenue $482K/yrExpenses $6.32M/yr
No trendCash runway ≈ 2 months from Jun 2026
Figures by year
When will Valion Bio be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Sep 2025, revenue was $482K and expenses $6.32M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2024 | $780K | $5.26M | −$4.48M |
| Dec 2023 | $1.18M | $9.42M | −$8.24M |
| Dec 2022 | $1.84M | $11.9M | −$10.1M |
| Dec 2021 | $1.26M | $6.89M | −$5.63M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.